Literature DB >> 7289450

[Rhabdomyolysis with acute renal failure due to bezafibrate].

H Heidemann, K D Bock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7289450     DOI： 10.1007/BF01698522

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN： 0023-2173


× No keyword cloud information.
  10 in total

1.  Nontraumatic rhabdomyolysis and acute renal failure.

Authors:  R A Grossman; R W Hamilton; B M Morse; A S Penn; M Goldberg
Journal:  N Engl J Med       Date:  1974-10-17       Impact factor: 91.245

2.  Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia.

Authors:  J F Bridgman; S M Rosen; J M Thorp
Journal:  Lancet       Date:  1972-09-09       Impact factor: 79.321

3.  Acute muscular syndrome associated with administration of clofibrate.

Authors:  T Langer; R I Levy
Journal:  N Engl J Med       Date:  1968-10-17       Impact factor: 91.245

4.  Clofibrate-induced muscle damage with myoglobinuria and cardiomyopathy.

Authors:  A G Smals; L V Beex; P W Kloppenborg
Journal:  N Engl J Med       Date:  1977-04-21       Impact factor: 91.245

5.  Clofibrate in hemodialyzed patients.

Authors:  K Kurokawa
Journal:  N Engl J Med       Date:  1977-04-21       Impact factor: 91.245

6.  Untoward effects of clofibrate in hemodialyzed patients.

Authors:  Y Kijima; T Sasaoka; M Kanayama; S Kubota
Journal:  N Engl J Med       Date:  1977-03-03       Impact factor: 91.245

7.  [Manganese serum levels of epileptics].

Authors:  H Hoffmann
Journal:  Klin Wochenschr       Date:  1980-02-01

8.  Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure.

Authors:  U Abshagen; W Kösters; B Kaufmann; P D Lang
Journal:  Klin Wochenschr       Date:  1980-09-01

9.  Seizure disorders and trace metals: manganese tissue levels in treated epileptics.

Authors:  P S Papavasilious; H Kutt; S T Miller; V Rosal; Y Y Wang; R B Aronson
Journal:  Neurology       Date:  1979-11       Impact factor: 9.910

10.  Clofibrate-induced muscle damage in patients with chronic renal failure.

Authors:  A M Pierides; F Alvarez-Ude; D N Kerr
Journal:  Lancet       Date:  1975-12-27       Impact factor: 79.321
  10 in total
  5 in total

Review 1.  Clinical features, pathogenesis and management of drug-induced rhabdomyolysis.

Authors:  C Köppel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Mar-Apr

Review 2.  Bezafibrate induced rhabdomyolysis.

Authors:  E Kanterewicz; R Sanmartí; J Riba; I Trias; J Autonell; J Brugués
Journal:  Ann Rheum Dis       Date:  1992-04       Impact factor: 19.103

3.  Acute muscular syndrome after bezafibrate.

Authors:  K D Bock
Journal:  Klin Wochenschr       Date:  1981-12-01

4.  [Bezafibrate-induced myolysis and myoglobinuria in patients with impaired renal function].

Authors:  K W Rumpf; M Barth; M Blech; H Kaiser; I Koop; R Arnold; F Scheler
Journal:  Klin Wochenschr       Date:  1984-04-16

Review 5.  Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia.

Authors:  J P Monk; P A Todd
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.